Disease · MONDO_0002752

ovarian adenocarcinoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. ovarian adenocarcinoma. Diseases, record MONDO_0002752. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0002752

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: ovarian adenocarcinoma; Open Targets
Open Targets ID: MONDO_0002752; Open Targets
Other names: adenocarcinoma of ovary, adenocarcinoma of the ovary, ovary adenocarcinoma; Open Targets
Disease Ontology: DOID:3713; Disease Ontology
NCI Thesaurus: C7700; NCI Thesaurus
Orphanet: ORPHA:213504; Orphanet
Highest stage of its drugs: Phase 2, for 6 of its 15 drugs, from ClinicalTrials.gov; Open Targets

Drugs15

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
ALDESLEUKIN	CHEMBL1201438	Protein	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
HU3S193	CHEMBL2109506		Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
IERAMILIMAB	CHEMBL4298009	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
NINTEDANIB	CHEMBL502835	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
SARGRAMOSTIM	CHEMBL1201670	Protein	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
SPARTALIZUMAB	CHEMBL4297831	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
DIANHYDROGALACTITOL	CHEMBL3137322	Small molecule	Phase 1/2	ClinicalTrials.gov	1	1	1	Drugs and targets
BEVACIZUMAB	CHEMBL1201583	Antibody	Phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets
FLUOROURACIL	CHEMBL185	Small molecule	Phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets
ING-1	CHEMBL2109263		Phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 15

See all 15 drugs

Targets29

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
FLT1	Vascular endothelial growth factor receptor	2	Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/2321	Drugs and targets
FLT4	Vascular endothelial growth factor receptor	2	Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/2324	Drugs and targets
KDR	Vascular endothelial growth factor receptor	2	Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/3791	Drugs and targets
PDGFRB	Platelet-derived growth factor receptor	2	Platelet-derived growth factor receptor beta inhibitor; Platelet-derived growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/5159	Drugs and targets
BRAF	Serine/threonine-protein kinase B-raf	1	Serine/threonine-protein kinase B-raf inhibitor	Phase 1	https://conductscience.org/library/genes/673	Drugs and targets
CRBN	CRL4(CRBN) E3 ubiquitin ligase	1	CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulator	Phase 1	https://conductscience.org/library/genes/51185	Drugs and targets
CSF2RA	Granulocyte-macrophage colony-stimulating factor receptor	1	Granulocyte-macrophage colony-stimulating factor receptor agonist	Phase 2	https://conductscience.org/library/genes/1438	Drugs and targets
CSF2RB	Granulocyte-macrophage colony-stimulating factor receptor	1	Granulocyte-macrophage colony-stimulating factor receptor agonist	Phase 2	https://conductscience.org/library/genes/1439	Drugs and targets
CUL4A	CRL4(CRBN) E3 ubiquitin ligase	1	CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulator	Phase 1	https://conductscience.org/library/genes/8451	Drugs and targets
DDB1	CRL4(CRBN) E3 ubiquitin ligase	1	CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulator	Phase 1	https://conductscience.org/library/genes/1642	Drugs and targets

1 to 10 of 29

See all 29 targets

Trials7

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03365791	PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies	Phase 2	76	2021-04-19	Small Cell Lung Cancer, Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Castration Resistant Prostate Adenocarcinoma, Soft Tissue Sarcoma, Ovarian Adenocarcinoma, Advanced Well-differentiated Neuroendocrine Tumors, Diffuse Large B Cell Lymphoma	IERAMILIMAB, SPARTALIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT01137071	Consolidation Therapy With Hu3S193 for Women With Ovarian, Primary Peritoneal or Fallopian Tube Cancer	Phase 2	29	2016-12-29	Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer	HU3S193	Its record names the disease	ClinicalTrials.gov
NCT01583322	Vargatef in Addition to First Line Chemotherapy With Interval Debulking Surgery in Patients With Ovarian Cancer	Phase 2	188		Ovarian Cancer	NINTEDANIB	Its record names the disease	ClinicalTrials.gov
NCT01183663	Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)	Phase 1	180		Advanced Cancers	BEVACIZUMAB, FLUOROURACIL, LENALIDOMIDE, LEUCOVORIN CALCIUM, OXALIPLATIN, SORAFENIB, TEMSIROLIMUS	Its record names the disease	ClinicalTrials.gov
NCT00051675	Phase I Study of a Monoclonal Antibody for Treatment of Advanced Adenocarcinomas	Phase 1	30		Adenocarcinoma	ING-1	Its record names the disease	ClinicalTrials.gov
NCT00001827	p53 Vaccine for Ovarian Cancer	Phase 2	21		Ovarian Neoplasm	ALDESLEUKIN, SARGRAMOSTIM	Its record names the disease	ClinicalTrials.gov
NCT03281681	A Multi-center Study of VAL-083 in Patients With Recurrent Platinum Resistant Ovarian Cancer	Phase 1/2	0		Ovarian Cancer	DIANHYDROGALACTITOL	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials2

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
PDR001+LAG525 On-treatment Period vs PDR001+LAG525 Extended Safety Follow-up Period: deaths from any cause	9 of 76	18 of 76	152	NCT03365791	Trial comparisons
PDR001+LAG525 On-treatment Period vs PDR001+LAG525 Extended Safety Follow-up Period: serious adverse events	31 of 76	4 of 76	152	NCT03365791	Trial comparisons

Papers from its trials9

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
41284952	DERIVED	1	PubMed
39671779	DERIVED	1	PubMed
38669064	DERIVED	1	PubMed
37185961	DERIVED	1	PubMed
36706645	DERIVED	1	PubMed
33664128	DERIVED	1	PubMed
33221969	DERIVED	1	PubMed
32712155	DERIVED	1	PubMed
23756764	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0002752

GET https://conductscience.org/api/diseases/v1/MONDO_0002752/targets?page=2

API reference For AI assistants